PGII
Pepsinogen II (PGII) is one of the two primary inactive precursors of pepsin, the other being Pepsinogen I (PGI). PGII is secreted by a variety of glands within the stomach, including the fundic glands, cardia glands, pyloric glands, and even in small quantities by the upper duodenal glands. This broad distribution pattern makes PGII an indicator of the overall condition of the gastric mucosa, rather than being specific to the fundic gland region alone. Key features and functions of PGII include:
Wide Distribution: The diverse origins of PGII from multiple glandular sites render it a comprehensive marker for assessing the general health of the gastric mucosa. Unlike PGI, which is more concentrated in the fundic glands, PGII is produced not only in the fundus but also in other parts of the stomach and the duodenum, enabling its serum levels to better reflect the global changes in the gastric mucosa.
Indicator of Gastric Mucosal Status: Serum PGII levels mirror the number of gastric mucosal glands and cells, indirectly showing the secretory function of different regions of the gastric mucosa. When the gastric mucosa undergoes atrophy, inflammation, or other pathologic changes, the secretion of PGII is affected, and these alterations can be detected through blood tests, reflecting the state of the mucosa.
In clinical applications:
Disease Diagnosis: Abnormal elevations or decreases in PGII levels, in conjunction with the ratio of PGI to PGII (PGI/PGII), are used as auxiliary diagnostic tools for conditions such as gastritis, peptic ulcers, and gastric cancer, particularly in gastric cancer screening where elevated levels have been observed in some patients with the disease.
Gastric Cancer Risk Assessment: PGII, along with its ratio to PGI, serves as a biomarker for early detection of gastric cancer, especially in populations where gastric cancer incidence is high, indicating potential malignant or benign gastric diseases.
Monitoring Treatment Effectiveness: For patients diagnosed with gastric diseases, regular monitoring of PGII levels can facilitate the evaluation of treatment efficacy and the recovery process of the gastric mucosa.
In summary, Pepsinogen II is a vital biomarker in the assessment of gastric health, playing a significant role in the diagnosis and risk assessment of gastric disorders, as well as in monitoring the therapeutic response in patients with established gastric diseases.
The performance data of the PGⅡ Rapid Quantitative Test Kit(CLIA)
Manufacturer | SEKBIO |
Parameter | PGⅡ |
Linearity | 1-100 ng/mL |
Detection limit | 1 ng/mL |
benchmark product | Biohit |
Test principle and procedure | PGⅡ: Add 10 μl of sample + 30 μl of Ra+ 30 μl of Rd incubation for 15 minutes. Wash with 200 μl of washing solution. Finally, add 100 μl of A + 100 μl of B. |
Six point calibration test results
Sample Concentration( ng/mL ) |
RLU | Average | CV | S/N | ||
0.18 | 1,063 | 1,072 | 1,104 | 1,080 | 2.00% | / |
1.57 | 10,345 | 10,274 | 9,867 | 10,162 | 2.54% | 9.41 |
5.89 | 44,788 | 43,517 | 43,878 | 44,061 | 1.49% | 40.81 |
10.83 | 86,422 | 85,636 | 84,684 | 85,581 | 1.02% | 79.27 |
52.10 | 390,857 | 400,849 | 396,978 | 396,228 | 1.27% | 366.99 |
133.06 | 757,058 | 764,506 | 754,528 | 758,697 | 0.68% | 702.71 |
Precision
Sample | RLU | Concentration | Sample | RLU | Concentration |
7.97 | 60,002 | 7.80 |
76.70 | 496,442 | 69.28 |
61,920 | 8.03 | 506,150 | 71.10 | ||
59,588 | 7.75 | 504,789 | 70.84 | ||
63,001 | 8.16 | 518,972 | 73.55 | ||
60,733 | 7.89 | 507,270 | 71.31 | ||
61,394 | 7.97 | 483,576 | 66.91 | ||
60,856 | 7.90 | 509,611 | 71.75 | ||
60,043 | 7.81 | 519,551 | 73.66 | ||
62,663 | 8.12 | 538,109 | 77.31 | ||
59,692 | 7.76 | 493,374 | 68.71 | ||
AVE | 60,989 | 7.92 | AVE | 507,784 | 71.44 |
SD | 1223.77 | 0.15 | SD | 15350.71 | 2.93 |
CV | 2.01% | 1.84% | CV | 3.02% | 4.09% |
Limit of detection
Sample | RLU | Concentration | ||
Ag Diluent | 235 | 248 | 0.01 | 0.01 |
251 | 221 | 0.01 | 0.00 | |
222 | 219 | 0.01 | 0.00 | |
194 | 260 | 0.00 | 0.01 | |
203 | 236 | 0.00 | 0.01 | |
263 | 268 | 0.01 | 0.01 | |
236 | 240 | 0.01 | 0.01 | |
269 | 267 | 0.01 | 0.01 | |
211 | 235 | 0.00 | 0.01 | |
221 | 207 | 0.00 | 0.00 | |
AVE | 235.300 | 0.007 | ||
SD | 22.95 | 0.00 | ||
AVE+2*SD | 0.00 | |||
Linear
Sample( ng/mL) | Dilution ratio | Concentration value | Average | ||
128.20 | 1.00 | 129.11 | 129.11 | 126.38 | 128.20 |
87.10 | 0.80 | 89.26 | 88.28 | 89.23 | 88.92 |
65.33 | 0.60 | 60.43 | 60.21 | 62.18 | 60.94 |
43.55 | 0.40 | 37.52 | 37.48 | 37.38 | 37.46 |
21.78 | 0.20 | 18.35 | 18.31 | 18.30 | 18.32 |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Method Comparison
